News

The open-label, randomized, controlled, global pivotal trial is enrolling patients with advanced primary, not yet treated, head and neck cancer. The trial’s main objective is to show a

OPN-305 is a new humanized IgG4 monoclonal antibody (MAb) against the Toll-Like Receptor 2 (TLR2), a target within the innate immune system. Evaluation of OPN-305 in MDS will

The company acquired Sivextro, as a part of its purchase through a subsidiary of Cubist Pharmaceuticals. Sivextro is a once-daily oxazolidinone antibiotic developed for both intravenous and oral

Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is

Prestalia is the first fixed-dose combination of perindopril arginine and amlodipine, may be used in patients whose blood pressure is not adequately controlled on monotherapy. The drug may

Assistant professor of biochemistry and molecular biology at Saint Louis University Mee-Ngan F. Yap, Ph.D studied staph that had been treated with the antibiotic azithromycin. During the study

If approved in the EU, ruxolitinib could provide the first targeted treatment option for these patients. PV is a chronic, incurable blood cancer associated with an overproduction of

Lupuzor (also called as Rigerimod, IPP-201101 and P140) received fast track designation from the US Food and Drug Administration (FDA) as well as approval to start Phase III

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in